2 weeks Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates Zacks

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of 19.39% and 17.76%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?